[go: up one dir, main page]

PE20081703A1 - Nuevos derivados triciclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen - Google Patents

Nuevos derivados triciclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen

Info

Publication number
PE20081703A1
PE20081703A1 PE2008000167A PE2008000167A PE20081703A1 PE 20081703 A1 PE20081703 A1 PE 20081703A1 PE 2008000167 A PE2008000167 A PE 2008000167A PE 2008000167 A PE2008000167 A PE 2008000167A PE 20081703 A1 PE20081703 A1 PE 20081703A1
Authority
PE
Peru
Prior art keywords
methyl
nitrobenzenosulfonamide
biphenyl
carbonyl
chloro
Prior art date
Application number
PE2008000167A
Other languages
English (en)
Inventor
Patrick Casara
Diguarher Thierry Le
Oliver Geneste
John Hickman
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of PE20081703A1 publication Critical patent/PE20081703A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

REFERIDA A UN COMPUESTO TRICICLICO DE FORMULA (I), DONDE A ES UN CICLO AROMATICO O NO AROMATICO QUE CONTIENE 5, 6 O 7 ESLABONES QUE PUEDE CONTENER 1 O 2 HETEROATOMOS TALES COMO O, S Y N. n Y n' SON 0, 1 O 2 DONDE LA SUMA DE n Y n' ESTA ENTRE 0 Y 4; R3 ES ARILO O HETEROARILO; X ES UN ALQUILENO C1-C6 OPCIONALMENTE SUSTITUIDO CON OXIGENO, CICLOALQUILENO, ARILENO, HETEROARILENO O SO2; R1 Y R2 SON H O UN COMPUESTO DE FORMULA (II); Y ES C=O O CH2; R5 ES H; R6 ES H O UN GRUPO -NR7R7' O -CH2-NR7R7'; R7 Y R7' SON H, ALQUILO C1-C6, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: N-({(4aR)-3-[(4'-CLORO[1,1'-BIFENIL]-2-IL)METIL]-2,3,4,4a,5,6-HEXAHIDRO-1H-PIRAZINO[1,2-a]QUINOLIN-8-IL}CARBONIL)-4-({(1R)-3-(DIMETILAMINO)-1-[(FENILSULFANIL)-METIL]PROPIL}AMINO)-3-NITROBENCENOSULFONAMIDA, N-({(4aR)-3-[(4'-CLORO[1,1'-BIFENIL]-2-IL)METIL]-2,3,4,4a,5,6-HEXAHIDRO-1H-PIRAZINO[1,2-a]QUINOLIN-8-IL}CARBONIL)-4-({(1R)-3-((1R,5S)-3-AZABICICLO[3.1.0]HEX-3-IL)-1-[(FENILSULFANIL)-METIL]PROPIL}AMINO)-3-NITROBENCENOSULFONAMIDA, N-({(10aß)-2-[(4'-CLORO[1,1'-BIFENIL]-2-IL)METIL]-1,2,3,4,10,10a-HEXAHIDROPIRAZINO[1,2-a]INDOL-8-IL}CARBONIL)-4-({(1R)-3-(DIMETILAMINO)-1-[(FENILSULFANIL)METIL]PROPIL}AMINO)-3-NITROBENCENOSULFONAMIDA. TAMBIEN ESTA REFERIDA A UN PROCEDIMIENTO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS TIENEN ACTIVIDAD PRO-APOPTOTICA Y SON UTILES EN EL TRATAMIENTO DEL CANCER
PE2008000167A 2007-02-02 2008-01-23 Nuevos derivados triciclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen PE20081703A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0700741A FR2912145B1 (fr) 2007-02-02 2007-02-02 Nouveaux derives tricycliques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number Publication Date
PE20081703A1 true PE20081703A1 (es) 2009-01-14

Family

ID=38219469

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000167A PE20081703A1 (es) 2007-02-02 2008-01-23 Nuevos derivados triciclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen

Country Status (45)

Country Link
US (1) US20080188460A1 (es)
EP (1) EP1953161B1 (es)
JP (1) JP2008266296A (es)
KR (1) KR100997027B1 (es)
CN (1) CN101270120A (es)
AP (1) AP2009004945A0 (es)
AR (1) AR065131A1 (es)
AT (1) ATE440842T1 (es)
AU (1) AU2008200499A1 (es)
BR (1) BRPI0800988A2 (es)
CA (1) CA2619897C (es)
CL (1) CL2008000318A1 (es)
CO (1) CO6230990A2 (es)
CR (1) CR10953A (es)
CY (1) CY1109637T1 (es)
DE (1) DE602008000104D1 (es)
DK (1) DK1953161T3 (es)
EA (1) EA014672B1 (es)
EC (1) ECSP099546A (es)
ES (1) ES2332337T3 (es)
FR (1) FR2912145B1 (es)
GE (1) GEP20115186B (es)
GT (1) GT200900217A (es)
HR (1) HRP20090565T1 (es)
IL (1) IL200128A0 (es)
JO (1) JO2616B1 (es)
MA (1) MA29725B1 (es)
MX (1) MX2008001504A (es)
MY (1) MY144633A (es)
NI (1) NI200900147A (es)
NZ (1) NZ565643A (es)
PA (1) PA8768301A1 (es)
PE (1) PE20081703A1 (es)
PL (1) PL1953161T3 (es)
PT (1) PT1953161E (es)
RS (1) RS51133B (es)
SA (1) SA08290043B1 (es)
SG (1) SG144892A1 (es)
SI (1) SI1953161T1 (es)
SV (1) SV2009003348A (es)
TN (1) TN2009000307A1 (es)
TW (1) TW200838532A (es)
UA (1) UA90726C2 (es)
WO (1) WO2008110691A1 (es)
ZA (1) ZA200801103B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2662080C (en) 2006-09-07 2012-07-17 F. Hoffmann-La Roche Ag A process for the manufacture of snac (salcaprozate sodium)
FR2933983B1 (fr) * 2008-07-15 2010-08-27 Servier Lab Nouveaux derives tricycliques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US8546377B2 (en) * 2009-04-23 2013-10-01 Abbvie Inc. Modulators of 5-HT receptors and methods of use thereof
US8518933B2 (en) * 2009-04-23 2013-08-27 Abbvie Inc. Modulators of 5-HT receptors and methods of use thereof
EP2421870B1 (en) * 2009-04-23 2016-03-09 AbbVie Inc. Modulators of 5-ht receptors and methods of use thereof
AU2010294292B2 (en) * 2009-09-10 2013-07-18 Novartis Ag Sulfonamides as inhibitors of Bcl-2 family proteins for the treatment of cancer
CN102584744B (zh) * 2011-01-06 2015-07-01 上海药明康德新药开发有限公司 4-(4-((2-(4-氯苯基)-5,5-二甲基环己基-1-烯)甲基)哌嗪-1-基)苯甲酸的合成方法
CN104039797B (zh) 2011-10-12 2016-06-01 南京奥昭生物科技有限公司 作为细胞凋亡诱导剂的杂环分子
TWI620733B (zh) * 2013-05-21 2018-04-11 拜耳作物科學股份有限公司 製備特定肟類及肟醚類之改良方法
JOP20190239A1 (ar) 2017-04-19 2019-10-09 Neurocrine Biosciences Inc مركبات مثبطة لـ vmat2 وتركيبات منها

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3899490A (en) * 1968-01-12 1975-08-12 Pfizer Hexahydro pyrazinoquinolines
DE2362539C2 (de) * 1973-12-17 1986-05-07 Merck Patent Gmbh, 6100 Darmstadt 2-Acyl-4-oxo-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isochinoline, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US5688950A (en) * 1996-04-23 1997-11-18 Neurogen Corporation Tricyclic aminoalkylcarboxamides; novel dopamine D3 receptor subtype specific ligands
JP2000169475A (ja) * 1998-07-24 2000-06-20 Dai Ichi Seiyaku Co Ltd ピラゾ―ル誘導体およびその塩
US6180629B1 (en) * 1998-08-14 2001-01-30 Cell Pathways, Inc. [4,5]-Fused-1,3-disubstituted-1,2-diazine-6-one derivatives with nitrogen containing substitutents in position one for the treatment of neoplasia
US6190629B1 (en) 1999-04-16 2001-02-20 Cbl Technologies, Inc. Organic acid scrubber and methods
US7919493B2 (en) * 2000-04-12 2011-04-05 Pharma Mar, S.A. Anititumoral ecteinascidin derivatives
CN1277828C (zh) * 2000-07-31 2006-10-04 霍夫曼-拉罗奇有限公司 哌嗪衍生物
ATE423104T1 (de) * 2001-11-03 2009-03-15 Astrazeneca Ab Quinazolin derivate als antitumor-mittel
CN1617725A (zh) * 2001-12-21 2005-05-18 王者制药研究发展有限公司 酪氨酰衍生物及其作为p2x7受体调节剂的用途
FR2841243B1 (fr) * 2002-06-19 2004-08-20 Servier Lab Nouveaux derives de 3-(4-oxo-4h-chromen-2yl)-(1h)-quinolein- 4-ones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP1578424A4 (en) * 2002-12-12 2007-08-08 Cytovia Inc SUBSTITUTED 1-BENZOYL-3-CYANOPYRROLO1,2-A | CHINOLINES AND THEIR ANALOGUES AS ACTIVATORS OF CASPASES AND INDUCTORS OF APOPTOSIS
WO2005049593A2 (en) * 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
EP1714961B1 (en) * 2004-02-12 2015-12-09 Mitsubishi Tanabe Pharma Corporation Indazole compound and pharmaceutical use thereof
US7790712B2 (en) * 2005-03-17 2010-09-07 Boehringer Ingelheim Pharmaceutical, Inc. Substituted [1,4]diazepino[1,2-A]indoles and azepino[1,2-A]indoles as anti-cytokine inhibitors
US8119640B2 (en) * 2008-02-12 2012-02-21 The Board Of Trustees Of The Leland Stanford Junior University Hedgehog pathway antagonists methods of use

Also Published As

Publication number Publication date
CA2619897C (fr) 2011-06-14
EA200800235A1 (ru) 2008-08-29
TN2009000307A1 (fr) 2010-12-31
CL2008000318A1 (es) 2008-08-08
NI200900147A (es) 2010-02-15
JP2008266296A (ja) 2008-11-06
IL200128A0 (en) 2010-04-15
AU2008200499A1 (en) 2008-08-21
EP1953161B1 (fr) 2009-08-26
CO6230990A2 (es) 2010-12-20
KR100997027B1 (ko) 2010-11-25
ECSP099546A (es) 2009-08-28
CR10953A (es) 2009-09-09
JO2616B1 (ar) 2011-11-01
PA8768301A1 (es) 2008-11-19
CA2619897A1 (fr) 2008-08-02
GEP20115186B (en) 2011-03-25
CY1109637T1 (el) 2014-08-13
AR065131A1 (es) 2009-05-20
MX2008001504A (es) 2009-02-24
SV2009003348A (es) 2010-02-01
DE602008000104D1 (de) 2009-10-08
SI1953161T1 (sl) 2009-12-31
BRPI0800988A2 (pt) 2008-11-25
AP2009004945A0 (en) 2009-08-31
SG144892A1 (en) 2008-08-28
RS51133B (sr) 2010-10-31
KR20080072574A (ko) 2008-08-06
FR2912145B1 (fr) 2009-03-06
EP1953161A1 (fr) 2008-08-06
MY144633A (en) 2011-10-14
FR2912145A1 (fr) 2008-08-08
WO2008110691A1 (fr) 2008-09-18
UA90726C2 (ru) 2010-05-25
EA014672B1 (ru) 2010-12-30
SA08290043B1 (ar) 2011-06-22
ZA200801103B (en) 2008-12-31
MA29725B1 (fr) 2008-09-01
DK1953161T3 (da) 2009-11-30
GT200900217A (es) 2011-09-14
TW200838532A (en) 2008-10-01
NZ565643A (en) 2009-05-31
ATE440842T1 (de) 2009-09-15
HRP20090565T1 (hr) 2009-12-31
PT1953161E (pt) 2009-10-26
CN101270120A (zh) 2008-09-24
PL1953161T3 (pl) 2010-01-29
ES2332337T3 (es) 2010-02-02
US20080188460A1 (en) 2008-08-07

Similar Documents

Publication Publication Date Title
PE20081703A1 (es) Nuevos derivados triciclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
PE20090276A1 (es) Compuestos derivados de imidazoquinolina como moduladores de tlr7
PE20070218A1 (es) COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA
PE20090423A1 (es) Compuestos moduladores de sirtuina
PE20081837A1 (es) Derivados de quinuclinidol como antagonistas de los receptores muscarinicos
AR077935A1 (es) Derivados de 3-amino-5 fenil-5,6-dihidro-2h-(1,4)oxazina
PE20090648A1 (es) Compuestos para el tratamiento de la hepatitis c
EA200801998A1 (ru) ПИРИДИН[3,4-b]ПИРАЗИНОНЫ
EA201491607A1 (ru) Модуляторы толлподобных рецепторов
PE20220134A1 (es) Compuestos de pirrolidina
AR069078A1 (es) Derivados de piridina y pirazina
UY28885A1 (es) 4-fenilamino-quinazolin-6-il-amidas referencia cruzada a solicitud(es) relacionada(s)
PE20110547A1 (es) Compuestos de isoindolina con actividad anticancerigena
EA200870127A1 (ru) Полициклические производные аминокислот и способы их применения
PE20120258A1 (es) Derivados de bencimidazol-pirrolidina como inhibidores del virus de la hepatitis c
PE20140690A1 (es) Benzoxazepinonas fusionadas como moduladoras de canales ionicos
EA200901373A1 (ru) Аминогетероциклические соединения
PE20120413A1 (es) ENANTIOMERO (S) DE 1'-{[5-(TRIFLUOROMETIL)FURAN-2-IL]METIL}ESPIRO[FURO[2,3-f][1,3]BENZODIOXOL-7,3'-INDOL]-2'(1'H)-ONA
PE20080409A1 (es) Compuestos que modulan en el receptor cb2
UY32462A (es) Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644
MA34604B1 (fr) Derives de la pyrazine en tant que bloqueurs de l'enac
EA201001595A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
AR078756A1 (es) Moduladores alostericos positivos (map)
PE20110405A1 (es) Derivados de piridino-piridinonas como inhibidores de la actividad de la tirosina quinasa de pdgf-r y/o flt-3 y su preparacion
EA201001196A1 (ru) Соединения 4-пиридинона и их применение для лечения рака

Legal Events

Date Code Title Description
FC Refusal